索拉非尼联合多柔比星对人乳腺癌MDA-MB-231细胞和人肺癌A549细胞抑制作用的研究

目的观察索拉非尼联合多柔比星对人乳腺癌MDA-MB-231细胞和人肺癌A549细胞的抑制作用。方法不同浓度索拉非尼联合多柔比星处理人乳腺癌MDA-MB-231细胞和人肺癌A549细胞。①以CCK-8法检测处理24、48和72 h后MDA-MB-231和A549的抑制率;②以细胞划痕试验观察受试细胞的迁移能力;③以印迹试验检测处理24 h后MDAMB-231细胞内P-ERK和Bcl-2的表达情况。结果索拉非尼联合多柔比星能显著抑制人肺癌A549细胞和人乳腺癌MDAMB-231细胞的体外增殖,且具时间依赖性;人乳腺癌MDA-MB-231细胞经不同浓度索拉非尼联合多柔比星处理24 h,P-ERK和Bcl-2蛋白的表达明显下调并呈剂量依赖性。结论索拉非尼联合多柔比星具有抑制人乳腺癌MDA-MB-231细胞和人肺癌A549细胞的增殖,诱导细胞凋亡的作用。

Effect of sorafenib combined with doxombicin on human breast cancer cell MDA-MB-231 and lung cancer cell A549

Objective To investigate the effect of sorafenib combined with doxorubicin on human breast cancer cell MDA-MB-231 and lung cancer cell A549. Methods To treat with MDA-MB-231cells and A549 cells using different concentrations of sorafenib combined with doxorubicin. ① CCK-8 was used to detect the inhibition rate in 24, 48 and 72 h.②To investigate the migration of MDA-MB-231 and A549 cells by wound-healing assay. ③The expression of P-ERK and Bcl-2 in MDA-MB-231 cells in 24 h was detected by Westernblot assay. Results Sorafenib combined with doxorubicin could significantly suppress the growth of human breast cancer MDA-MB-231 cells in vitro, in a time dependent; after different concentrations of sorafenib combined with doxorubicin treatment of cancer cells in 24 h, the protein expressing of P-ERK and Bcl-2 was significantly lowered. Conclusion Sorafenib combined with doxorubicin might inhibit the proliferation of human breast cancer cells MDA-MB-231 and lung cancer cells A549.